JP2024524552A5 - - Google Patents

Info

Publication number
JP2024524552A5
JP2024524552A5 JP2024500258A JP2024500258A JP2024524552A5 JP 2024524552 A5 JP2024524552 A5 JP 2024524552A5 JP 2024500258 A JP2024500258 A JP 2024500258A JP 2024500258 A JP2024500258 A JP 2024500258A JP 2024524552 A5 JP2024524552 A5 JP 2024524552A5
Authority
JP
Japan
Prior art keywords
refractory
patient
multiple myeloma
received
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524552A (ja
Filing date
Publication date
Priority claimed from GBGB2109894.2A external-priority patent/GB202109894D0/en
Priority claimed from GBGB2112976.2A external-priority patent/GB202112976D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/068974 external-priority patent/WO2023281007A1/en
Publication of JP2024524552A publication Critical patent/JP2024524552A/ja
Publication of JP2024524552A5 publication Critical patent/JP2024524552A5/ja
Pending legal-status Critical Current

Links

JP2024500258A 2021-07-08 2022-07-07 多発性骨髄腫の治療に使用するためのメルフルフェン Pending JP2024524552A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2109894.2A GB202109894D0 (en) 2021-07-08 2021-07-08 Novel treatments
GB2109894.2 2021-07-08
GB2112976.2 2021-09-10
GBGB2112976.2A GB202112976D0 (en) 2021-09-10 2021-09-10 Novel treatments
PCT/EP2022/068974 WO2023281007A1 (en) 2021-07-08 2022-07-07 Melflufen for use in the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
JP2024524552A JP2024524552A (ja) 2024-07-05
JP2024524552A5 true JP2024524552A5 (enExample) 2025-07-10

Family

ID=82702963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500258A Pending JP2024524552A (ja) 2021-07-08 2022-07-07 多発性骨髄腫の治療に使用するためのメルフルフェン

Country Status (5)

Country Link
US (1) US20240307480A1 (enExample)
EP (1) EP4366721A1 (enExample)
JP (1) JP2024524552A (enExample)
TW (1) TW202317084A (enExample)
WO (1) WO2023281007A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121349A1 (en) * 2022-12-08 2024-06-13 Oncopeptides Ab Therapeutic treatment for haematological cancer based on the level of t-cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
DK2701720T3 (en) 2011-04-28 2017-10-09 Oncopeptides Ab Lyophilized preparation with cytotoxic dipeptides
SMT202000058T1 (it) 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
US12152087B2 (en) 2018-10-18 2024-11-26 Oncopeptides Innovation Ab Deuterated melflufen compounds
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Similar Documents

Publication Publication Date Title
JP2020172502A5 (enExample)
US11826317B2 (en) Combination therapy with notch and PD-1 or PD-L1 inhibitors
CN106102745B (zh) 治疗和预防移植物抗宿主病的方法
EP2961388B1 (en) Drug combinations
JP2017525713A5 (enExample)
CA3142960A1 (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
CN103228142A (zh) 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
Mateos et al. Novel generation of agents with proven clinical activity in multiple myeloma
US11241448B2 (en) Methods for cancer therapy
Nifosì et al. Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology
EP3860612A1 (en) Immunoablative therapies
CA2984464A1 (en) Treatment for multiple myeloma (mm)
CN112839658A (zh) 用于治疗癌症的组合疗法
JP2024524552A5 (enExample)
KR20240142500A (ko) Psma-표적화 방사성제약 및 체크포인트 억제제 조합 요법
TW202131946A (zh) 持續性免疫療法
US20100184732A1 (en) Method of long-term treatment of graft-versus-host disease using topical active corticosteroids
JP2024514163A5 (enExample)
Alia biological treatment options of multiple myeloma
TW202120092A (zh) 化合物用於預防或治療移植物抗宿主病的用途
WO2022016231A1 (en) Methods of treatment
JP2025503213A (ja) Ｎｔｓｒ１標的化放射性医薬品およびチェックポイント阻害剤併用療法
Lonial et al. Oral Selinexor Shows Single Agent Activity Enhanced With PI or IMID Combinations in Refractory Multiple Myeloma (MM)
HK40124218A (zh) 延长移植物和受体存活期的组合物和方法
WO2025160930A1 (zh) 母帕司汀(Muparfostat)治疗胰腺癌的用途